Immunome IMNM Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -5,947.9%-2,719pp | -3,228.8%-809pp | -2,419.9%-636pp | -1,784.1%+210pp | -1,994.3%+1,388pp | |
| Net margin | -5,593.8%-2,534pp | -3,060%-759pp | -2,301.3%-614pp | -1,687.1%+188pp | -1,875.2%+1,365pp | |
| Returns | ||||||
| Return on equity | -50.1%+1.9pp | -52.1%+40.9pp | -93%-11.8pp | -81.2%-12.0pp | -69.2%+125pp | |
| Return on invested capital | -746.6%— | —— | —— | -203.4%+408pp | -611.6%+322pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 21.7×+7.0× | 14.7×+5.8× | 8.9×-3.2× | 12.1×+1.6× | 10.5×+6.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $5.20-28.3% | $7.26+142% | $3.00-3.0% | $3.09-20.0% | $3.87+25.2% | |
| Valuation | ||||||
| Market capitalization | $2.47B+4.4% | $2.37B+133% | $1.02B+31.3% | $776.15M+32.6% | $585.18M-11.7% | |
| Price / sales | 616.2×+275× | 341.4×+236× | 105.3×+43.7× | 61.7×+8.2× | 53.5×-19.8× | |
| Price / book | 4.2×+0.5× | 3.7×-0.1× | 3.9×+1.0× | 2.9×+1.0× | 1.9×-1.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Immunome's ratios come from?
- Every ratio is computed from Immunome's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
